The University of Tokyo · 의학
Yuta Suzuki 교수의 연구실은 심혈관 질환 예방과 만성질환 관리에 초점을 맞춘 실생활 데이터 기반의 임상 연구를 수행합니다. 당뇨병 환자를 대상으로 SGLT2 억제제의 심혈관계적 효과와 혈압, 혈액포도당 수치가 동맥류 및 동맥류성 동맥류 위험에 미치는 영향을 분석하며, 특히 젊은 성인의 고혈압 예방 전략과 심부전 발생 위험과의 연관성에 대해 깊이 있는 연구를 진행하고 있습니다. 이는 조기 선제적 관리 전략 수립에 중요한 기초 자료를 제공합니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
The risks for subsequent development of HF, MI, AP, stroke, and AF were comparable between individual SGLT2 inhibitors. This is the first study comparing the wide-range cardiovascular outcomes of patients with DM treated with individual SGLT2 inhibitors using large-scale real-world data.
The purpose of this study was to investigate differences in the support leg joint moment and moment power between side-step (SS) and cross-step (CS) cutting techniques with a prescribed 90 degrees cutting angle. Ground reaction forces (1,000Hz) and three-dimensional kinematics (250Hz) of SS and CS cutting techniques were collected from 20 male college athletes. Normalised peak knee extension moment was larger in the SS technique than in the CS technique (0.40 +/- 0.10 in SS; 0.26 +/- 0.08 in CS)
Abstract Aims Data on the dose-dependent association of blood pressure (BP) and fasting plasma glucose (FPG) level with the risk of aortic dissection (AD) and aortic aneurysm (AA) are limited. Methods and results This observational cohort study included 3 358 293 individuals registered in a health checkup and claims database in Japan [median age, 43 (36–51) years; 57.2% men]. Individuals using BP- or glucose-lowering medications or those with a history of cardiovascular disease were excluded. In
CVH metrics can stratify the risk for hypertension in non-hypertensive adults aged 20-39 years. These findings have important public health implications for the screening and prevention of hypertension. Improving CVH metrics may prevent the risk of developing hypertension in young adults.
Background The prevalence of hypertension subtypes changes with age. However, little is known regarding the age-dependent association of hypertension subtypes with incident heart failure (HF). Methods and Results We conducted an observational cohort study including 2 612 570 people (mean age, 44.0 years; 55.0% men). No participants were taking blood pressure-lowering medications or had a known history of cardiovascular disease. Participants were categorized as aged 20 to 49 years (n=1 825 756),
Our analysis using large-scale real-world data demonstrated the potential advantage of SGLT2 inhibitors over DPP4 inhibitors in patients with MAFLD and DM.
